157 related articles for article (PubMed ID: 17786950)
41. Chaetocin inhibits RANKL-induced osteoclast differentiation through reduction of Blimp1 in Raw264.7 cells.
Zhao N; Tsuda H; Murofushi T; Imai K; Ochiai K; Yang P; Suzuki N
Life Sci; 2015 Dec; 143():1-7. PubMed ID: 26514304
[TBL] [Abstract][Full Text] [Related]
42. Ameloblastin attenuates RANKL-mediated osteoclastogenesis by suppressing activation of nuclear factor of activated T-cell cytoplasmic 1 (NFATc1).
Chaweewannakorn W; Ariyoshi W; Okinaga T; Fujita Y; Maki K; Nishihara T
J Cell Physiol; 2019 Feb; 234(2):1745-1757. PubMed ID: 30105896
[TBL] [Abstract][Full Text] [Related]
43. Inhibitory effect of minocycline on osteoclastogenesis in mouse bone marrow cells.
Nagasawa T; Arai M; Togari A
Arch Oral Biol; 2011 Sep; 56(9):924-31. PubMed ID: 21377143
[TBL] [Abstract][Full Text] [Related]
44. Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis.
Gong W; Dou H; Liu X; Sun L; Hou Y
Clin Exp Pharmacol Physiol; 2012 Oct; 39(10):886-93. PubMed ID: 23013134
[TBL] [Abstract][Full Text] [Related]
45. Inhibition of differentiation and function of osteoclasts by dimethyl sulfoxide (DMSO).
Yang C; Madhu V; Thomas C; Yang X; Du X; Dighe AS; Cui Q
Cell Tissue Res; 2015 Dec; 362(3):577-85. PubMed ID: 26224539
[TBL] [Abstract][Full Text] [Related]
46. Interleukin (IL)-12 mediates the anti-osteoclastogenic activity of CpG-oligodeoxynucleotides.
Amcheslavsky A; Bar-Shavit Z
J Cell Physiol; 2006 Apr; 207(1):244-50. PubMed ID: 16402377
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population.
Nagata N; Kitaura H; Yoshida N; Nakayama K
Bone; 2003 Oct; 33(4):721-32. PubMed ID: 14555278
[TBL] [Abstract][Full Text] [Related]
48. Ascorbic acid inhibits osteoclastogenesis of RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand (RANKL) in vitro.
Xiao XH; Liao EY; Zhou HD; Dai RC; Yuan LQ; Wu XP
J Endocrinol Invest; 2005 Mar; 28(3):253-60. PubMed ID: 15952411
[TBL] [Abstract][Full Text] [Related]
49. Cannabinoid receptor-2 selective antagonist negatively regulates receptor activator of nuclear factor kappa B ligand mediated osteoclastogenesis.
Geng DC; Xu YZ; Yang HL; Zhu GM; Wang XB; Zhu XS
Chin Med J (Engl); 2011 Feb; 124(4):586-90. PubMed ID: 21362286
[TBL] [Abstract][Full Text] [Related]
50. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
[TBL] [Abstract][Full Text] [Related]
51. Interleukin 29 inhibits RANKL-induced osteoclastogenesis via activation of JNK and STAT, and inhibition of NF-κB and NFATc1.
Peng Q; Luo A; Zhou Z; Xuan W; Qiu M; Wu Q; Xu L; Kong X; Zhang M; Tan W; Xue M; Wang F
Cytokine; 2019 Jan; 113():144-154. PubMed ID: 30001863
[TBL] [Abstract][Full Text] [Related]
52. Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis in BMMs by Suppressing NF-κB and STAT3 Activities.
Joung YH; Darvin P; Kang DY; Sp N; Byun HJ; Lee CH; Lee HK; Yang YM
PLoS One; 2016; 11(7):e0159891. PubMed ID: 27447722
[TBL] [Abstract][Full Text] [Related]
53. Interleukin-4 directly inhibits tumor necrosis factor-alpha-mediated osteoclast formation in mouse bone marrow macrophages.
Kitaura H; Nagata N; Fujimura Y; Hotokezaka H; Tatamiya M; Nakao N; Yoshida N; Nakayama K
Immunol Lett; 2003 Sep; 88(3):193-8. PubMed ID: 12941478
[TBL] [Abstract][Full Text] [Related]
54. Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis.
Bharti AC; Takada Y; Aggarwal BB
J Immunol; 2004 May; 172(10):5940-7. PubMed ID: 15128775
[TBL] [Abstract][Full Text] [Related]
55. Antiosteoclastogenic activity of silicate-based materials antagonizing receptor activator for nuclear factor kappaB ligand-induced osteoclast differentiation of murine marcophages.
Hung CJ; Kao CT; Chen YJ; Shie MY; Huang TH
J Endod; 2013 Dec; 39(12):1557-61. PubMed ID: 24238446
[TBL] [Abstract][Full Text] [Related]
56. Monocrotaline Suppresses RANKL-Induced Osteoclastogenesis In Vitro and Prevents LPS-Induced Bone Loss In Vivo.
Wei CM; Su YJ; Qin X; Ding JX; Liu Q; Song FM; Zong SH; Xu J; Zhou B; Zhao JM
Cell Physiol Biochem; 2018; 48(2):644-656. PubMed ID: 30025412
[TBL] [Abstract][Full Text] [Related]
57. Quercetin suppresses bone resorption by inhibiting the differentiation and activation of osteoclasts.
Woo JT; Nakagawa H; Notoya M; Yonezawa T; Udagawa N; Lee IS; Ohnishi M; Hagiwara H; Nagai K
Biol Pharm Bull; 2004 Apr; 27(4):504-9. PubMed ID: 15056855
[TBL] [Abstract][Full Text] [Related]
58. The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.
Kim HS; Suh KS; Sul D; Kim BJ; Lee SK; Jung WW
Int J Mol Med; 2012 Feb; 29(2):169-77. PubMed ID: 22038020
[TBL] [Abstract][Full Text] [Related]
59. Decoy receptor 3 suppresses RANKL-induced osteoclastogenesis via down-regulating NFATc1 and enhancing cell apoptosis.
Cheng CP; Sheu MJ; Sytwu HK; Chang DM
Rheumatology (Oxford); 2013 Apr; 52(4):609-22. PubMed ID: 23221330
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of osteoclast differentiation and bone resorption by sauchinone.
Han KY; Yang D; Chang EJ; Lee Y; Huang H; Sung SH; Lee ZH; Kim YC; Kim HH
Biochem Pharmacol; 2007 Sep; 74(6):911-23. PubMed ID: 17662251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
